← FDA DRUG APPROVALS

FDA ANDA · ANDA202418

LAMIVUDINE AND ZIDOVUDINE

Sponsor: AUROBINDO PHARMA LTD

APPLICATION
ANDA202418
TYPE
ANDA
ORIGINAL APPROVAL
2012-05-15
LATEST ACTION
2019-07-22
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

LAMIVUDINE AND ZIDOVUDINEDiscontinued
LAMIVUDINE 150MG, ZIDOVUDINE 300MG · TABLET · ORAL

Approval history

2019-07-22Labeling · Supplement 8 · standardAP
2019-07-22Labeling · Supplement 6 · standardAP
2019-07-22Labeling · Supplement 4 · standardAP
2019-07-22Labeling · Supplement 7 · standardAP
2019-07-22Labeling · Supplement 10 · standardAP
2012-05-15UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →